重组人VEGFR2(KDR)(血管内皮生长因子受体2)

特别提示：包括重组人VEGFR2(KDR)(血管内皮生长因子受体2)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人VEGFR2(KDR)(血管内皮生长因子受体2)
英文名称：Recombinant Human Vascular Endothelial Growth Factor Receptor 2
产品货号：JN1379
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Ala20-Glu764在C端带有Fc标签。

VEGFR2/KDR质量控制：＞95%(还原性SDS-PAGE)

VEGFR2/KDR制剂：冻干品

VEGFR2/KDR保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

VEGFR2/KDR复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于VEGFR2/KDR：
Human Vascular endothelial growth factor receptor 2(KDR, VEGFR-2) is a member of the class III subfamily of receptor tyrosine kinases (RTKs). KDR is involved in a number of fundamental biological processes such as the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It also plays an essential role in promoting proliferation, survival, migration and differentiation of endothelial cells, reorganization of the actin cytoskeleton. VEGFR2 is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo.The adaptor protein SHB has been shown to interact with VEGFR2 in receptor tyrosine kinase signaling. In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposis sarcoma lesions. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

我公司销售的重组人VEGFR2(KDR)(血管内皮生长因子受体2)，重组VEGFR2，rVEGFR2，重组Vascular Endothelial Growth Factor Receptor 2，重组血管内皮生长因子受体2，重组人VEGFR2，Recombinant Human Vascular Endothelial Growth Factor Receptor 2，rhKDR，重组KDR，rhVEGFR2，重组人血管内皮生长因子受体2，重组人Vascular Endothelial Growth Factor Receptor 2，重组人KDR，rKDR质量上佳，价格普惠，欢迎广大新老客户踊跃订购。